Drug Profile
OCT 1547
Alternative Names: OCT-1547Latest Information Update: 30 Aug 2017
Price :
$50
*
At a glance
- Originator Oscotec
- Class Osteoporosis therapies; Small molecules
- Mechanism of Action Osteoclast inhibitors; RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 30 Aug 2017 Discontinued - Phase-I for Osteoporosis in USA (PO)
- 11 Feb 2016 Phase-I clinical trials in Osteoporosis in USA (PO) prior to February 2016
- 16 Sep 2008 Preclinical trials in Osteoporosis in South Korea (PO)